We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Metastatic hormone receptor-positive breast cancer in CDK 4/6 era: An outcome audit.
- Authors
Lakkavalli, Rajeev Krishnappa; Pehalajani, Jitendra Kumar; Tirumala, Venkatesh; Babu, Govind K; Loknatha, Dassappa; Jacob, Linu Abraham; Babu, Suresh M C; Rudresha, A H; Kadabur, Lokesh Nagendrappa; Saldanha, Smitha C; Giri, G V
- Abstract
<bold>Background: </bold>The treatment landscape of metastatic hormone receptor (HR) positive breast cancer has been changed in recent years. Availability of CDK 4/6 inhibitor and other hormone therapy has changed the treatment algorithm for these patient, we retrospectively analyzed our metastatic HR positive breast cancer patients.<bold>Materials and Methods: </bold>In this study, we retrospectively analyzed the case records of hr positive metastatic breast cancer patient treated at department of medical oncology from October 2016 to September 2018. Demographical characteristics, site of metastasis, objective response and clinical benefit response and toxicity profile were analyzed.<bold>Results: </bold>We treated a total of 178 patients of MBC with HT at our center during the study period. One hundred fifty-two patients received HT alone (control group) and 26 patients received HT and CDK 4/6 inhibitor (study group). The median age of patients was 56 and 58 years in the control group and study group. The ORR was 41.7 versus 57.9 (95% CI [1.01-2.56]), and the CBR was 66.1% versus 78.9%; (CI [1.18-3.56]) (P < 0.05) of the patients in control and study groups, respectively.<bold>Conclusions: </bold>Among patients with HR-positive, advanced breast cancer, hormone therapy is efficacious addition of CDK 4/6 inhibitor improve the efficacy with tolerable side effects.
- Subjects
PROTEIN metabolism; SURVIVAL; AUDITING; PROTEIN kinase inhibitors; CELL receptors; RETROSPECTIVE studies; PROGNOSIS; METASTASIS; TRANSFERASES; BREAST tumors; LONGITUDINAL method
- Publication
Journal of Cancer Research & Therapeutics, 2021, Vol 17, Issue 3, p994
- ISSN
0973-1482
- Publication type
journal article
- DOI
10.4103/jcrt.JCRT_853_18